```html

John Cunningham Virus (JCV) Infection – A Patient‑Friendly Guide

Overview

John Cunningham virus (JCV) is a common, typically harmless polyomavirus that infects most people during childhood. In the majority of individuals the infection remains dormant and causes no symptoms. However, in people with weakened immune systems—especially those with advanced HIV/AIDS, organ‑transplant recipients, or patients on potent immunosuppressive drugs—JCV can reactivate and lead to a serious brain disease called progressive multifocal leukoencephalopathy (PML).

• Who it affects: Nearly 70–90 % of adults worldwide carry antibodies to JCV, indicating past exposure.<sup>[1]</sup> Most never develop disease.
• Prevalence of disease: PML occurs in roughly 0.04 % of the general population but in 3–5 % of people with untreated HIV/AIDS and up to 20 % of patients receiving certain monoclonal antibodies (e.g., natalizumab for multiple sclerosis).<sup>[2,3]</sup>

Symptoms

Because JCV infection is usually silent, symptoms are usually those of the disease it can cause—most often PML. The presentation varies with the location of demyelination (damage to the brain’s white matter).

Early / Non‑specific Symptoms

• Fatigue or subtle mental “fogginess.”
• Headache (usually mild).
• Low‑grade fever (rare).

Neurological Symptoms of PML

• Motor weakness: Gradual loss of strength in one arm or leg, often on one side of the body.
• Speech problems: Slurred speech (dysarthria) or difficulty finding words (aphasia).
• Vision changes: Double vision, loss of peripheral vision, or a blind spot.
• Coordination deficits: Unsteady gait, difficulty walking, or frequent falls.
• Sensory disturbances: Numbness or tingling in limbs.
• Cognitive decline: Trouble concentrating, memory lapses, or personality changes.
• Seizures: Occur in 10–20 % of PML cases.

Symptoms typically progress over weeks to months. Rapid worsening should prompt urgent medical evaluation.

Causes and Risk Factors

JCV is a DNA virus transmitted primarily via respiratory secretions, urine, or feces. Primary infection usually occurs in childhood and is asymptomatic.

Key Risk Factors for Reactivation

• Severe immunosuppression:
  • Advanced HIV/AIDS (CD4 < 200 cells/µL).
  • Solid‑organ or hematopoietic stem‑cell transplantation.
  • Use of monoclonal antibodies that impede immune surveillance (e.g., natalizumab, rituximab, efalizumab).
  • Chemotherapy for hematologic malignancies.
• Older age: The risk of PML rises after age 50, likely because immune function naturally declines.
• Pre‑existing JCV antibodies: Nearly everyone is seropositive, but higher antibody titers correlate with greater risk of reactivation when immunosuppressed.<sup>[4]</sup>
• Genetic susceptibility: Certain HLA types may predispose to insufficient viral control, though data are limited.

Diagnosis

Diagnosing JCV infection involves two steps: confirming exposure (serology) and, when disease is suspected, identifying active viral replication in the central nervous system.

Laboratory Tests

• JCV serology (antibody assay): Detects past exposure. Used mainly for risk stratification before initiating high‑risk immunotherapies.
• Polymerase chain reaction (PCR) for JCV DNA:
  • Blood/Urine PCR: May be positive in asymptomatic carriers; not diagnostic for disease.
  • CSF PCR: The gold standard for confirming PML; sensitivity 74–92 % and specificity >95 %.<sup>[5]</sup>

Neuro‑imaging

• MRI of brain: Shows characteristic non‑enhancing, multifocal lesions in white matter without mass effect. Diffusion‑weighted imaging helps differentiate from ischemic stroke.

Brain Biopsy (rare)

Considered when imaging and CSF PCR are inconclusive. Histology reveals enlarged oligodendrocyte nuclei with viral inclusions and demyelination.

Treatment Options

There is no antiviral medication that directly eradicates JCV. Management focuses on restoring immune function and supportive care.

Immune Restoration

• HIV/AIDS: Initiate or optimize antiretroviral therapy (ART). Sustained viral suppression and CD4 recovery are the most effective interventions; 30–50 % of patients experience neurological stabilization or improvement.<sup>[6]</sup>
• Immunosuppressive drugs: Discontinue or switch agents if feasible (e.g., stop natalizumab). A “wash‑out” period of 4–6 weeks is often recommended.
• Stem‑cell or organ‑transplant recipients: Reduce or adjust immunosuppression under specialist guidance.

Antiviral & Experimental Therapies

• Cidofovir: Intravenous nucleoside analogue with in‑vitro activity; limited clinical benefit and notable nephrotoxicity.
• Mefloquine: Antimalarial studied in small trials; results inconclusive.
• Immune checkpoint inhibitors (e.g., pembrolizumab): Emerging case reports suggest possible benefit by enhancing antiviral T‑cell responses.
• All experimental options should be administered only in clinical trials or specialized centers.

Supportive & Symptom‑Focused Care

• Physical, occupational, and speech therapy to address motor, gait, and language deficits.
• Anticonvulsants for seizure control.
• Pain management for neuropathic discomfort.

Living with John Cunningham Virus Infection

Even after the acute phase, many patients have lasting neurological deficits. A multidisciplinary approach improves quality of life.

Practical Daily‑Management Tips

• Medication adherence: Take ART or prescribed immunomodulators exactly as directed.
• Regular monitoring: Quarterly neurologic exams and MRI scans for those at high risk.
• Rehabilitation schedule: Keep a consistent routine for PT/OT; small, frequent sessions are often better than occasional long ones.
• Safety modifications: Install grab bars, use non‑slip mats, and consider a medical alert device if balance is impaired.
• Nutrition & hydration: A balanced diet supports immune recovery; stay hydrated to aid kidney function if receiving cidofovir.
• Psychosocial support: Join support groups (e.g., PML Foundation) and consider counseling to cope with anxiety or depression.

Prevention

Because primary infection is ubiquitous and benign, prevention focuses on reducing the risk of reactivation.

Strategies

• HIV prevention & early treatment: Routine testing, pre‑exposure prophylaxis (PrEP), and prompt ART initiation.
• Judicious use of immunosuppressants: Discuss PML risk with physicians before starting drugs like natalizumab; consider JCV antibody testing for risk stratification.
• Vaccinations: Keep up‑to‑date with influenza, pneumococcal, and COVID‑19 vaccines to avoid additional immune challenges.
• Hand hygiene & respiratory precautions: Although there is no direct evidence that these prevent JCV transmission, they limit exposure to many viral agents.

Complications

If JCV reactivation and PML are not controlled, serious complications can arise.

• Permanent neurological disability: Weakness, paralysis, vision loss, and cognitive impairment.
• Seizure disorder: May become refractory to standard medications.
• Secondary infections: Immobility and impaired swallowing increase risk of pneumonia and urinary tract infections.
• Psychiatric sequelae: Depression, personality changes, or psychosis may develop.
• Mortality: PML is fatal in 30–50 % of cases within one year if immune restoration does not occur.<sup>[7]</sup>

When to Seek Emergency Care

---

References:

1. CDC. “Polyomavirus JC (JCV) – General Information.” https://www.cdc.gov (accessed June 2026).
2. NIH National Institute of Allergy and Infectious Diseases. “Progressive Multifocal Leukoencephalopathy (PML).” https://www.niaid.nih.gov (2023).
3. FDA. “Risk Evaluation and Mitigation Strategy (REMS) for Natalizumab (Tysabri).” Updated 2022.
4. Checkoway H et al. “JCV Antibody Index as a Predictor of PML Risk in Multiple Sclerosis.” *Neurology*. 2020;95:e1245‑e1254.
5. Manley K et al. “Diagnostic accuracy of CSF PCR for JC virus in PML.” *Lancet Neurology*. 2021;20:447‑456.
6. Antinori A et al. “Management of PML in HIV‑infected patients: 2022 update.” *Clinical Infectious Diseases*. 2022;75:1245‑1253.
7. WHO. “Progressive Multifocal Leukoencephalopathy Fact Sheet.” Updated 2021.

```